Affiliation:
1. Postgraduate Program in Biophotonics Medicine Universidade Nove de Julho, UNINOVE São Paulo SP Brazil
2. Centro Universitário Univates – CCBS Lajeado RS Brazil
Abstract
AbstractPurposePhotobiomodulation therapy (PBM) is a versatile technique for treating skin diseases. Melasma, a chronic hyperpigmentation condition, has recently been associated with vascular features and dermal photoaging and poses significant management challenges. We review the recent literature on melasma etiology and the evidence supporting PBM as a therapeutic modality for melasma treatment.MethodsWe conducted a comprehensive literature search in three different databases from May to August 2023, focusing on studies published in the past 10 years. The inclusion criteria comprised full‐text studies investigating low‐power lasers and/or light‐emitting diodes (LEDs) in in vitro or in vivo models, as well as clinical trials. We excluded studies discussing alternative melasma therapies or lacking experimental data. We identified additional studies by searching the reference lists of the selected articles.ResultsWe identified nine relevant studies. Clinical studies, in agreement with in vitro experiments and animal models, suggest that PBM effectively reduces melasma‐associated hyperpigmentation. Specific wavelengths (red: 630 nm; amber: 585 and 590 nm; infrared: 830 and 850 nm) at radiant exposures between 1 and 20 J/cm2 exert modulatory effects on tyrosinase activity, gene expression, and protein synthesis of melanocytic pathway components, and thus significantly reduce the melanin content. Additionally, PBM is effective in improving the dermal structure and reducing erythema and neovascularization, features recently identified as pathological components of melasma.ConclusionPBM emerges as a promising, contemporary, and non‐invasive procedure for treating melasma. Beyond its role in inhibiting melanogenesis, PBM shows potential in reducing erythema and vascularization and improving dermal conditions. However, robust and well‐designed clinical trials are needed to determine optimal light parameters and to evaluate the effects of PBM on melasma thoroughly.
Funder
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Subject
Dermatology,Radiology, Nuclear Medicine and imaging,Immunology,General Medicine,Immunology and Allergy
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Photobiomodulation Literature Watch November 2023;Photobiomodulation, Photomedicine, and Laser Surgery;2024-08-09
2. An Update on New and Existing Treatments for the Management of Melasma;American Journal of Clinical Dermatology;2024-06-19
3. Phototherapy for pigmentary disorders;Photodermatology, Photoimmunology & Photomedicine;2024-04-14
4. Characteristics of dermal vascularity in melasma and solar lentigo;Photodermatology, Photoimmunology & Photomedicine;2024-02-14